2023 年 10 月至 2024 年 1 月，西班牙对婴儿呼吸道合胞病毒下呼吸道感染住院进行 nirsevimab 免疫预防的早期效果评估。
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
机构信息
Vaccine Research Department, Fisabio-Public Health, Valencia, Spain.
These authors contributed equally to this article and share first authorship.
出版信息
Euro Surveill. 2024 Feb;29(6). doi: 10.2807/1560-7917.ES.2024.29.6.2400046.
Abstract
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
摘要
单克隆抗体 nirsevimab 在西班牙预防呼吸道合胞病毒 (RSV) 阳性的下呼吸道感染 (LRTI) 住院的有效性至少为 70%（2023 年 10 月至 2024 年 1 月），该地区于 9 月底开始实施普遍免疫计划（覆盖范围：79-99%）。在三个地区的九家医院进行的多中心主动监测中，两种方法设计（筛查和阴性检测）证实了高度保护作用。但该疫苗对 RSV 阴性 LRTI 住院没有保护作用。这些中期结果可能为公共卫生决策提供指导。
相似文献
1
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
Euro Surveill. 2024 Feb;29(6). doi: 10.2807/1560-7917.ES.2024.29.6.2400046.
2
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Lancet Infect Dis. 2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30.
3
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.
4
Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
Lancet Child Adolesc Health. 2024 Oct;8(10):721-729. doi: 10.1016/S2352-4642(24)00143-3. Epub 2024 Aug 26.
5
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
6
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.
BMC Infect Dis. 2024 Sep 6;24(1):924. doi: 10.1186/s12879-024-09642-0.
7
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
8
The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study.
Front Public Health. 2024 Aug 16;12:1441786. doi: 10.3389/fpubh.2024.1441786. eCollection 2024.
9
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Nurs Womens Health. 2024 Feb;28(1):75-79. doi: 10.1016/j.nwh.2023.11.002. Epub 2023 Dec 6.
10
Nirsevimab: Alleviating the burden of RSV morbidity in young children.
J Paediatr Child Health. 2024 Oct;60(10):489-498. doi: 10.1111/jpc.16643. Epub 2024 Aug 16.
引用本文的文献
1
Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia.
Front Immunol. 2025 Aug 18;16:1624007. doi: 10.3389/fimmu.2025.1624007. eCollection 2025.
2
The Number Needed to Immunize (NNI) to Assess the Benefit of a Prophylaxis Intervention with Monoclonal Antibodies Against RSV.
Vaccines (Basel). 2025 Jul 25;13(8):791. doi: 10.3390/vaccines13080791.
3
Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years.
Lancet Reg Health West Pac. 2025 Aug 8;61:101654. doi: 10.1016/j.lanwpc.2025.101654. eCollection 2025 Aug.
4
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
5
The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy.
Front Public Health. 2025 Jul 3;13:1604331. doi: 10.3389/fpubh.2025.1604331. eCollection 2025.
6
Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.
Pediatr Pulmonol. 2025 Jul;60(7):e71059. doi: 10.1002/ppul.71059.
7
Pediatric respiratory syncytial virus rehospitalization rate - a retrospective observational study from Switzerland.
BMC Pediatr. 2025 Jul 12;25(1):550. doi: 10.1186/s12887-025-05887-z.
8
Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity.
Ital J Pediatr. 2025 Jul 2;51(1):205. doi: 10.1186/s13052-025-01998-6.
9
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign.
Vaccines (Basel). 2025 Jun 10;13(6):623. doi: 10.3390/vaccines13060623.
10
Development and Validation of a New Set of Primers for Identification of Circulating Lineages and Palivizumab/Nirsevimab Resistance in HRSV Isolates from Cabo Verde.
Trop Med Infect Dis. 2025 Jun 10;10(6):160. doi: 10.3390/tropicalmed10060160.
本文引用的文献
1
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
Euro Surveill. 2024 Jan;29(4). doi: 10.2807/1560-7917.ES.2024.29.4.2400033.
2
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
3
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300606.
4
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
5
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.
Lancet Respir Med. 2023 Apr;11(4):341-353. doi: 10.1016/S2213-2600(22)00414-3. Epub 2022 Nov 10.
6
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
7
Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain.
Influenza Other Respir Viruses. 2022 Mar;16(2):328-339. doi: 10.1111/irv.12937. Epub 2021 Nov 24.
8
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
9
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.
N Engl J Med. 2020 Jan 23;382(4):309-317. doi: 10.1056/NEJMoa1901229.
10
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
Lancet. 2016 Dec 3;388(10061):2775-2782. doi: 10.1016/S0140-6736(16)31921-3. Epub 2016 Oct 27.
Zotero 插件